Mild elevation of N-acetylaspartic acid and macrocephaly: diagnostic problem
- PMID: 14696913
- DOI: 10.1177/08830738030180111601
Mild elevation of N-acetylaspartic acid and macrocephaly: diagnostic problem
Abstract
Patients with slightly increased excretion of N-acetylaspartic acid in urine, together with macrocephaly, present a dignostic dilemma for Canavan's disease. We describe a 13-year-old male patient with macrocephaly, mild developmental delay, increased signal intensity in the basal ganglia bilaterally, partial cortical blindness, and retinitis pigmentosa. Although the clinical course and magnetic resonance imaging findings did not resemble typical Canavan's disease, N-acetylaspartic acid excretion in the patient's urine was slightly elevated, 99.90 +/- 4.00 microg/mg creatinine, whereas the normal control range was < 83 microg/mg creatinine. Cultured skin fibroblasts from the patient showed no aspartoacylase activity. Cloning of genomic DNA isolated from the patient's fibroblasts showed an intronic mutation, specifically deletion of -2A and -3C at the acceptor site of exon 3 and disrupting the normal splicing of the gene. A second mutation was found in exon 6, 863 A-->G in aspartoacylase complementary DNA, causing a tyrosine-to-cysteine (Y288C) amino acid substitution. Expression of the mutation on exon 6 showed normal aspartoacylase activity. These data suggest that expression of the mutation may help to understand the enzyme defect in a patient with slightly increased N-acetylaspartic acid excretion.
Similar articles
-
Molecular basis of Canavan's disease: from human to mouse.J Child Neurol. 2003 Sep;18(9):604-10. doi: 10.1177/08830738030180090601. J Child Neurol. 2003. PMID: 14572138 Review.
-
Mild-onset presentation of Canavan's disease associated with novel G212A point mutation in aspartoacylase gene.Ann Neurol. 2006 Feb;59(2):428-31. doi: 10.1002/ana.20787. Ann Neurol. 2006. PMID: 16437572
-
Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease.Am J Med Genet. 1988 Feb;29(2):463-71. doi: 10.1002/ajmg.1320290234. Am J Med Genet. 1988. PMID: 3354621
-
[Magnetic resonance tomography and localized proton spectroscopy in 2 siblings with Canavan's disease].Rofo. 1995 Sep;163(3):238-44. doi: 10.1055/s-2007-1015980. Rofo. 1995. PMID: 7548871 German.
-
Canavan disease: diagnosis and molecular analysis.Genet Test. 1997;1(1):21-5. doi: 10.1089/gte.1997.1.21. Genet Test. 1997. PMID: 10464621 Review.
Cited by
-
Parkinson's disease: oxidative stress and therapeutic approaches.Neurol Sci. 2010 Oct;31(5):531-40. doi: 10.1007/s10072-010-0245-1. Epub 2010 Mar 10. Neurol Sci. 2010. PMID: 20221655 Review.
-
Relationship between enzyme properties and disease progression in Canavan disease.J Inherit Metab Dis. 2013 Jan;36(1):1-6. doi: 10.1007/s10545-012-9520-z. Epub 2012 Aug 1. J Inherit Metab Dis. 2013. PMID: 22850825
-
Upregulation of N-acetylaspartic acid alters inflammation, transcription and contractile associated protein levels in the stomach and smooth muscle contractility.Mol Biol Rep. 2009 Jan;36(1):201-6. doi: 10.1007/s11033-007-9167-2. Epub 2007 Oct 18. Mol Biol Rep. 2009. PMID: 17943458
-
Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity.Hum Mutat. 2017 May;38(5):524-531. doi: 10.1002/humu.23181. Epub 2017 Feb 14. Hum Mutat. 2017. PMID: 28101991 Free PMC article.
-
Mutational analysis of aspartoacylase: implications for Canavan disease.Brain Res. 2007 May 7;1148:1-14. doi: 10.1016/j.brainres.2007.02.069. Epub 2007 Mar 3. Brain Res. 2007. PMID: 17391648 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical